We argue that the long-term focus on HTA's technical inputs and related processes has failed because it implicitly endorses the state's framework. It misses the importance of making a philosophical case against a system whose primary flaw is that patients are servile to the state's economic interests.
Make the case against the state's imposition of economic interests as the only consideration
January 21, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children
February 18, 2026 - - Latest News -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
Targeted blood cancer treatments proposed for funding in New Zealand
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Australian Biotech

